Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173 , July 2010

Antihypertensive drug development: current challenges and future opportunities

  • Peter U. Feig, MD

      Affiliations

    • Cardiovascular Clinical Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
    • Corresponding Author InformationCorresponding author: Peter U. Feig, MD, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., 126 E. Lincoln Ave, RY34 A200, P.O. Box 2000, Rahway, NJ 07065-0900. Tel: 732-594-3229.
    • ,
  • Sophie Roy, PhD

      Affiliations

    • Cardiovascular Basic Research, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey
    • ,
  • Robert J. Cody, MD

      Affiliations

    • Global Scientific Affairs, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Rahway, New Jersey

Received 26 March 2010 ,Accepted 14 April 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1933-1711(10)00088-4

doi: 10.1016/j.jash.2010.04.003

Journal of the American Society of Hypertension
Volume 4, Issue 4 , Pages 163-173 , July 2010

Article Tools

* Image Usage & Resolution